TY  - JOUR
AB  - Background: Epithelial-to-mesenchymal transition (EMT) is a crucial step in lung cancer pathogenesis. Among others, cancer-associated fibroblasts (CAFs) are reported to regulate this process. Objectives: To investigate the prognostic and clinical impact, we analyzed CD34 + and SMA+ CAFs in non-small cell lung cancer (NSCLC). Methods: Retrospectively, immunohistochemistry was performed to study stromal protein expression of both CD34 and SMA in 304 NSCLC patients with pTNM stage I-III disease. All tissue samples were embedded on tissue microarrays (TMAs). Results: Our analysis revealed an association for CD34+ CAFs with G1/2 tumors and adenocarcinoma histology. Moreover CD34+ CAFs were identified as an independent prognostic factor (both for progression free survival [PFS] and overall survival [OS] in stage I-III NSCLC). Besides, SMA+ expression correlated with higher pTNM-tumor stages and lymphatic spread (pN stage). In turn, SMA-negativity was associated with improved PFS, but no prognostic impact was found on OS. Of interest, neither CD34+ CAFs nor SMA+ CAFs were associated with the primary tumor size, localization and depth of infiltration (pT stage). Conclusions: CD34 was identified as an independent prognostic marker in pTNM stage I-III NSCLC. Moreover, loss of CD34+ CAFs might influence the dedifferentiation of the NSCLC tumor from its cell origin. Finally, SMA+ CAFs are more prevalent in NSCLC tumors of higher stages and lymphonodal positive NSCLC.
AU  - Schulze, Arik Bernard
AU  - Schmidt, Lars Henning
AU  - Heitkötter, Birthe Franziska
AU  - Huss, Sebastian
AU  - Mohr, Michael
AU  - Marra, Alessandro
AU  - Hillejan, Ludger
AU  - Görlich, Dennis
AU  - Barth, Peter
AU  - Rehkämper, Jan
AU  - Evers, Georg Heribert
DA  - 2019-11-24
DO  - 10.17879/63079605492
KW  - Cancer associated fibroblast
KW  - CD34
KW  - EMT
KW  - NSCLC
KW  - SMA
LA  - eng
N1  - Thoracic Cancer 11 (2020) 1, 120–129
N1  - Finanziert über die DEAL-Vereinbarung mit Wiley 2019-2022.
PY  - 2019-11-24
TI  - Prognostic impact of CD34 and SMA in cancer-associated fibroblasts in stage I–III NSCLC
UR  - https://nbn-resolving.org/urn:nbn:de:hbz:6-33069482979
Y2  - 2024-11-21T23:40:16
ER  -